COMMUNIQUÉS West-GlobeNewswire

TearLab Corporation Announces Voluntary Delisting From Toronto Stock Exchange

16/03/2018 - 12:00

SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced that it has applied and received approval for a voluntary delisting of its common [...]

Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial

16/03/2018 - 12:00

SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]

Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights

16/03/2018 - 12:00

- Positive topline results from pivotal LEAP 1 trial announced in September 2017, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $86.9 million cash and investments as of December 31 [...]

Cannabis Wheaton Income Corp. Provides Update on the Initial Development of FV Pharma Inc. Facility

16/03/2018 - 12:00

VANCOUVER, British Columbia, March 16, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX.V:CBW) (" Cannabis Wheaton " or the " Company ") is pleased to provide an update on the initial development of its [...]

Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28

16/03/2018 - 12:00

COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in [...]

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease

16/03/2018 - 11:38

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered [...]

Genesis HealthCare Reports Fourth Quarter and Fiscal Year End 2017 Results

16/03/2018 - 11:00

KENNETT SQUARE, Pa., March 16, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN ), one of the largest post-acute care providers in the United States, today announced operating results for [...]

Articles of Association

16/03/2018 - 10:54

ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) Articles of Association most recently amended by the shareholders at the AGM held on 12 March 2018 ALKArticlesOfAssociation_12032018_final_approvedByAGM

Vistin Pharma ASA : Torbjørn Kjus joins Vistin to develop new business area

16/03/2018 - 10:48

Oslo, Norway, 16 March 2018 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) has entered into agreements with Torbjørn Kjus and Kenneth Tveter for the development of a new business area within energy trading activities. " [...]

Genetic Technologies Limited Announces Further Collaborative Research with The University of Melbourne to Broaden the Applicability of the BREVAGenplus® Breast Cancer Risk Assessment Test

16/03/2018 - 10:00

MELBOURNE, Australia, March 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq: GENE ) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic [...]

DHAIS plc : Statement re Withdrawal from NEX Exchange

16/03/2018 - 08:01

16 March 2018 DHAIS PLC ("DHAIS" or "the Company") PROPOSED WITHDRAWAL FROM NEX EXCHANGE GROWTH MARKET DHAIS announces that the Company is today giving notice of its intention to withdraw its ordinary shares in the [...]

Probiodrug to present at 255th ACS National Meeting & Exposition

16/03/2018 - 07:01

Probiodrug to present at 255th ACS National Meeting & Exposition The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer's Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical [...]

argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

16/03/2018 - 07:01

Grant to fund research of novel targets involved in regulation of locally-released TGF-beta, a protein active in immunosuppression March 16, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: [...]

Veloxis Increases Share Capital in Connection with Exercise of Warrants

16/03/2018 - 05:00

Company Release no. 04/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 16 March 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's [...]

Maple Leaf to Apply for a Dealer’s Licence with the Office of Controlled Substances within Health Canada

15/03/2018 - 23:11

CALGARY, Alberta, March 15, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“ Maple Leaf ” or the “ Company ”) (TSXV:MGW) (OTCQB:MGWFF) is pleased to announce that it has engaged Cannabis Compliance Inc. (“ CCI [...]

Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update

15/03/2018 - 22:59

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018 [...]

Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

15/03/2018 - 22:17

Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidance Plans underway to address capital structure and advance metreleptin development program VANCOUVER, British Columbia, [...]

Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital

15/03/2018 - 22:10

VANCOUVER, British Columbia, March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN ), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]

Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents

15/03/2018 - 22:00

MENLO PARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT ), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, [...]